Search
Search
The occurrence of brain tumors is influenced by a combination of genetic and environmental factors. A small percentage of brain tumors occur in individuals with a family history of brain tumors or a family history of genetic syndromes. This genetic trait usually increases the risk of developing brain tumors in a particular population. Mutations in brain tumor susceptibility genes increase an individual's risk of developing brain tumors to some extent.
Alfa Cytology uses brain tumor genetic testing to detect multiple genetic brain tumor susceptibility genes and analyze their mutation information. We can also assess the relative risk of brain tumor development by combining existing mutations with the relationship between the genes and brain tumorigenesis.
The study of epigenetic changes (such as aberrant methylation and altered transcription factor binding) can provide insight into important oncogenic pathways. Methylation changes often activate or silence genes, and epigenomic changes can affect gene expression and the rate of brain tumor progression. We use next-generation sequencing (NGS) and microarray technology (methylation microarrays) to detect methylation patterns and other epigenetic changes in brain tumors to meet the rapidly changing needs of the brain tumor research field.
We collect brain tumor tissue samples to generate muta-genomic data for each tissue sample and calculate a combinatorial index of genetic heterogeneity within the brain tumor based on the muta-genomic data. This serves as an indicator of genetic heterogeneity within brain tumors and provides a quantitative tool for stratified analysis of brain tumor patients.
We provide comprehensive genetic testing and genetic counseling services to help our clients understand how genetic factors may affect their own and their relatives' risk of developing brain tumors.
Alfa Cytology focuses on the detection and analysis of the genetic risk of brain tumors, which will help more researchers to detect the risk of brain tumors in patients at an early stage so that early treatment can be done. Please contact our staff for the latest protocols.